Clinical Trials
Numerous clinical trials evaluate Daprodustat primarily for managing anemia associated with chronic kidney disease, alongside secondary indications including peripheral vascular disease, wound healing, and allergic bronchopulmonary aspergillosis. Spanning Phase 1 pharmacokinetic evaluations through Phase 4 comparative efficacy and safety trials, these studies—sponsored by entities such as GlaxoSmithKline, Qilu Pharmaceutical, and USRC Kidney Research—range in status from recruiting and active to completed or terminated.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07300111 | NOT_YET_RECRUITING | Anaemia |
Qilu Pharmaceutical Co., Ltd. |
2025-12-31 | PHASE3 |
| NCT07755683 | NOT_YET_RECRUITING | Chronic Kidney Disease (Stages 3b-5); Anemia Associated With Chronic Kidney Disease |
Services Hospital, Lahore |
2026-09-01 | |
| NCT05682326 | COMPLETED | Anaemia |
GlaxoSmithKline |
2023-09-06 | PHASE3 |
| NCT05951192 | COMPLETED | Anemia; Renal Insufficiency, Chronic; Renal Anemia |
USRC Kidney Research |
2023-07-01 | PHASE4 |
| NCT05682326 | Recruiting | Anaemia |
GlaxoSmithKline |
2023-09-06 | Phase 3 |
| NCT05951192 | Active not recruiting | Anemia|Renal Insufficiency Chronic|Renal Anemia |
USRC Kidney Research|GlaxoSmithKline |
2023-07-01 | Phase 4 |
| NCT03457701 | COMPLETED | Anaemia |
GlaxoSmithKline |
2019-07-30 | PHASE2 |
| NCT04640311 | COMPLETED | Anaemia |
GlaxoSmithKline |
2020-12-18 | PHASE1 |
| NCT02876835 | COMPLETED | Anaemia |
GlaxoSmithKline |
2016-09-27 | PHASE3 |
| NCT04640311 | Completed | Anaemia |
GlaxoSmithKline |
2020-12-18 | Phase 1 |
| NCT02879305 | COMPLETED | Anaemia; Aspergillosis, Allergic Bronchopulmonary |
GlaxoSmithKline |
2016-09-28 | PHASE3 |
| NCT03409107 | COMPLETED | Anaemia |
GlaxoSmithKline |
2018-03-05 | PHASE3 |
| NCT03029208 | COMPLETED | Anaemia |
GlaxoSmithKline |
2017-05-11 | PHASE3 |
| NCT03029247 | COMPLETED | Anaemia |
GlaxoSmithKline |
2017-07-27 | PHASE2 |
| NCT03400033 | COMPLETED | Anaemia |
GlaxoSmithKline |
2018-09-05 | PHASE3 |
| NCT03446612 | TERMINATED | Anaemia |
GlaxoSmithKline |
2019-01-10 | PHASE2 |
| NCT02791763 | COMPLETED | Anaemia |
GlaxoSmithKline |
2016-06-06 | PHASE3 |
| NCT03223337 | COMPLETED | Anaemia |
GlaxoSmithKline |
2017-07-24 | PHASE1 |
| NCT02969655 | COMPLETED | Anaemia |
GlaxoSmithKline |
2016-11-21 | PHASE3 |
| NCT03493386 | COMPLETED | Anaemia |
GlaxoSmithKline |
2018-04-24 | PHASE1 |
| NCT03239522 | COMPLETED | Anaemia |
GlaxoSmithKline |
2017-10-10 | PHASE1 |
| NCT02829320 | COMPLETED | Anaemia |
GlaxoSmithKline |
2016-08-08 | PHASE3 |
| NCT02243306 | COMPLETED | Anaemia |
GlaxoSmithKline |
2014-10-24 | PHASE1 |
| NCT01831804 | COMPLETED | Wound Healing |
GlaxoSmithKline |
2013-06-17 | PHASE1 |
| NCT02689206 | COMPLETED | Anaemia |
GlaxoSmithKline |
2016-02-17 | PHASE2 |
| NCT02075463 | TERMINATED | Anemia; Anaemia |
GlaxoSmithKline |
2014-06-11 | PHASE2 |
| NCT02371603 | COMPLETED | Anaemia |
GlaxoSmithKline |
2015-02-11 | PHASE1 |
| NCT02231190 | COMPLETED | Tendon Injuries |
GlaxoSmithKline |
2015-01-15 | PHASE1 |
| NCT01977573 | COMPLETED | Anaemia |
GlaxoSmithKline |
2013-10-31 | PHASE2 |
| NCT02293148 | COMPLETED | Anaemia |
GlaxoSmithKline |
2014-11-17 | PHASE1 |
| NCT01977482 | COMPLETED | Anaemia |
GlaxoSmithKline |
2013-11-01 | PHASE2 |
| NCT01920594 | COMPLETED | Surgical Procedures |
GlaxoSmithKline |
2013-10-31 | PHASE2 |
| NCT02019719 | COMPLETED | Anaemia |
GlaxoSmithKline |
2013-11-05 | PHASE2 |
| NCT01406340 | TERMINATED | Anaemia |
GlaxoSmithKline |
2011-08-30 | PHASE1 |
| NCT01587924 | COMPLETED | Anaemia |
GlaxoSmithKline |
2012-05-23 | PHASE2 |
| NCT01587898 | COMPLETED | Anaemia |
GlaxoSmithKline |
2012-05-17 | PHASE2 |
| NCT01673555 | COMPLETED | Anaemia |
GlaxoSmithKline |
2012-05-15 | PHASE1 |
| NCT02135848 | COMPLETED | Vascular Disease, Peripheral |
GlaxoSmithKline |
2010-10-15 | PHASE2 |
| NCT01319006 | COMPLETED | Anaemia |
GlaxoSmithKline |
2011-02-25 | PHASE1 |
| NCT01376232 | COMPLETED | Anaemia |
GlaxoSmithKline |
2010-11-08 | PHASE1 |
| NCT00935831 | COMPLETED | Kidney Disease |
GlaxoSmithKline |
2009-08-12 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2025-12-23)
Check the
Daprodustat (GSK1278863)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
- Daprodustat (GSK1278863) Solubility in DMSO
- Daprodustat (GSK1278863) Stock Solution
- Daprodustat (GSK1278863) Storage
- Daprodustat (GSK1278863) Stability
- Daprodustat (GSK1278863) Molecular Weight
- Daprodustat (GSK1278863) SMILES
- Daprodustat (GSK1278863) CAS Number
- Daprodustat (GSK1278863) Chemical Structure (2D and 3D)
- Daprodustat (GSK1278863) SDS|MSDS
Note: Technical data last updated: Sep 1, 2026.